Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Dosing of Study Drug in Patients Undergoing PCI
The dosing regimen for percutaneous coronary intervention (PCI) procedures in the fondaparinux (fonda) and enoxaparin (enox) groups according to time after last subcutaneous (sc) dose of study drug and use of glycoprotein (GP) IIb/IIIa antagonists. All study drugs were given in a double-blind, double-dummy fashion. IV = intravenous; UFH = unfractionated heparin.
|
